Ignite Creation Date:
2025-12-24 @ 9:59 PM
Ignite Modification Date:
2025-12-25 @ 7:36 PM
Study NCT ID:
NCT03111732
Status:
COMPLETED
Last Update Posted:
2021-12-03
First Post:
2017-04-12
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-06-14
Start Date Type:
ACTUAL
Primary Completion Date:
2020-07-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-11-08
Completion Date Type:
ACTUAL
First Submit Date:
2017-04-12
First Submit QC Date:
None
Study First Post Date:
2017-04-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-03-22
Results First Submit QC Date:
None
Results First Post Date:
2021-04-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-12-01
Last Update Post Date:
2021-12-03
Last Update Post Date Type:
ACTUAL